Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide
Open Access
- 1 April 2008
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (7), 1579-1586
- https://doi.org/10.1038/sj.bjp.0707685
Abstract
Background and purpose: Patients commonly take complementary medicines in conjunction with conventional drugs without clear evidence of safety or the risk of herb–drug interactions. The aim of this study was to assess potential pharmacokinetic (PK) and pharmacodynamic (PD) interactions between St John's wort and gliclazide in healthy subjects with different cytochrome P450 2C9 (CYP2C9) genotypes. Experimental approach: A crossover controlled study was conducted in 21 healthy subjects. Each received gliclazide (80 mg) either alone or during 15 days treatment with St John's wort. The area under the plasma concentration–time curve (AUC0−∞), apparent clearance (CL/F) and elimination half‐life (t 1/2) of gliclazide and incremental changes in glucose and insulin AUC0−4 were compared. CYP2C9*2 and CYP2C9*3 alleles were identified using PCR followed by restriction enzyme digestion analysis. Key results: St John's wort significantly altered gliclazide pharmacokinetics in all except for four healthy subjects. The mean ratio and 90% confidence interval (CI) of gliclazide AUC0−∞ and CL/F were 0.67 (0.55–0.81) and 1.50 (1.24–1.81), respectively, after St John's wort treatment. St John's wort decreased gliclazide t 1/2, with mean ratio and 90% CI of 0.85 (0.74–0.93). There were no significant changes in glucose or insulin AUC0−4 after St John's wort treatment and no significant differences according to CYP2C9 genotype. Conclusions and implications: Treatment with St John's wort significantly increases the apparent clearance of gliclazide which is independent of CYP2C9 genotype. People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy. British Journal of Pharmacology (2008) 153, 1579–1586; doi:10.1038/sj.bjp.0707685; published online 21 January 2008This publication has 42 references indexed in Scilit:
- Identification of the human cytochromes P450 catalysing the rate‐limiting pathways of gliclazide eliminationBritish Journal of Clinical Pharmacology, 2007
- Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjectsBritish Journal of Clinical Pharmacology, 2007
- Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic DrugsClinical Pharmacokinetics, 2005
- Interaction of St John's wort with conventional drugs: systematic review of clinical trialsBMJ, 2004
- Quantification of gliclazide by semi-micro high-performance liquid chromatography: application to a bioequivalence study of two formulations in healthy subjectsJournal of Pharmaceutical and Biomedical Analysis, 2004
- Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsBritish Journal of Clinical Pharmacology, 2004
- α-Endosulfine, a positional and functional candidate gene for type 2 diabetes: molecular screening, association studies, and role in reduced insulin secretionMolecular Genetics and Metabolism, 2004
- Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X ReceptorThe Journal of pharmacology and experimental therapeutics, 2003
- Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetesBritish Journal of Clinical Pharmacology, 2000
- The metabolism of gliclazide in manXenobiotica, 1985